Helixgate

Helixgate

Uncategorized

Moderna continues bird flu vax study, but limits work in the U.S.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. Big news: I’ve convinced at least one other STAT staffer to re-read “The Odyssey” with me ahead of the movie this summer. Starting today, that means we’ll read three books (chapters), or about 1,500 lines, per week for the next eight weeks. Care to join us? 

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. Big news: I’ve convinced at least one other STAT staffer to re-read “The Odyssey” with me ahead of the movie this summer. Starting today, that means we’ll read three books (chapters), or about 1,500 lines, per week for the next eight weeks. Care to join us? 

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs

Published

on

Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will fund “general corporate purposes,” including …

Continue Reading

Uncategorized

Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy

Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy

Published

on

Sanofi CEO Paul Hudson bet big on immunology. When Belén Garijo takes over as CEO next week, she will have to decide whether to continue that wager.

The direction Garijo elects to pursue will likely …​ ​Read More

Continue Reading

Uncategorized

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Read More

Published

on

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Read More

Continue Reading
Advertisement

Trending